Abstract: The present invention relates to a method for purification of hemopexin and haptoglobin and provides a method in which a solution containing hemopexin and haptoglobin is titrated to a range of specific pH values without a step of precipitating haptoglobin by salt addition, followed by separating and purifying hemopexin and haptoglobin individually.
Type:
Application
Filed:
January 27, 2022
Publication date:
February 1, 2024
Applicant:
GREEN CROSS CORPORATION
Inventors:
Jee Won AHN, Jong Ho LEE, Mi Ji YU, Eun Jung LEE, Ji Eun KANG, Ji Hoon KIM, Nohra PARK, Dong Hoon KANG, Ju Ho LEE
Abstract: An ADAMTS13 mutant protein having an improved escaping rate against an autoantibody and a composition that is suitable for preventing or treating thrombotic diseases are disclosed. By efficiently avoiding autoantibodies known to have high binding affinity to the main domain of ADAMTS13, the ADAMTS13 variant protein of the present invention can be used as an effective therapeutic composition for various thrombotic diseases, such as TTP (thrombotic thrombocytopenic purpura), in which the presence of such autoantibodies is the main etiology, and can stably maintain the biological activity thereof when administered into a body. In addition, a newly identified site within ADAMTS13, which is recognized by an autoantibody can be used in screening novel ADAMTS13 variants having an improved autoantibody escaping rate by applying a combination of various mutations within the corresponding site.
Type:
Application
Filed:
October 25, 2021
Publication date:
December 21, 2023
Applicant:
GREEN CROSS CORPORATION
Inventors:
Hyun-Ja NAM, Sung Ho HWANG, Heechun KWAK, Gahee CHOI, Suyong KIM, Yu Young KIM, Yongmin LEE, Chae Mok LEE, Sunhye SHIN, Young Eun KWON, Seunghyun JO
Abstract: A method for production of a Varicella Zoster Virus surface protein antigen is disclosed. The method for production of a Varicella Zoster Virus surface protein antigen is an effective production method capable of obtaining the Varicella Zoster Virus surface protein antigen in high yield and high purity. Therefore, the method is useful for production of the Varicella Zoster Virus surface protein antigen for use as a vaccine composition for preventing or treating varicella or herpes zoster.
Type:
Application
Filed:
July 6, 2021
Publication date:
August 17, 2023
Applicant:
GREEN CROSS CORPORATION
Inventors:
Kwang Bae LEE, Mi Suk KIM, Jung Ae LIM, Yoo Min 16924, Seung Ryel HAN, Ji Yeon KIM, Ji Sung YOU
Abstract: An anti-CD3 antibody and a pharmaceutical composition, and their uses are disclosed. The anti-CD3 antibody are useful for treating or preventing cancer. The antibody has high affinity and specificity for CD3 and thus can be effectively used in cancer prevention or treatment.
Type:
Application
Filed:
October 3, 2022
Publication date:
June 22, 2023
Applicants:
Green Cross Corporation, Mogam Institute For Biomedical Research
Inventors:
Ki Su KIM, Jun Hong Jeong, Ae Rin Yoon, Eun Jung Song, Hye Ji Choi, Ok Jae Lim, Yun Jung Lee, Hyung Kwon Lim, Jong Wha Won
Abstract: A method for purification of a sulfatase using metal chelating chromatography without using tags such as His-tag, etc. is disclosed. An embodiment provides a method for purifying a sulfatase including the steps of: (a) providing a sulfatase-containing solution comprising one or a plurality of impurities; (b) performing a first chromatographic separation of the sulfatase-containing solution using a metal affinity chromatography resin; (c) performing a second chromatographic separation using a cation exchange chromatography resin; and (d) performing a final chromatographic separation using an anion exchange chromatography resin, wherein the impurities are removed thereby.
Type:
Grant
Filed:
August 31, 2017
Date of Patent:
February 21, 2023
Assignee:
GREEN CROSS CORPORATION
Inventors:
Denis Feshin, Byung Hyun Park, Yong Won Shin
Abstract: Provided are a compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same and a use thereof, where the compound having a 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
Type:
Application
Filed:
November 12, 2020
Publication date:
January 5, 2023
Applicants:
YUHAN CORPORATION, GREEN CROSS CORPORATION
Inventors:
Dong-Hoon KIM, Jae-Eun JOO, Eui-Chul LEE, Tae-Dong HAN, Seung-Yub SHIN, Sool-Ki KWON, Ji-Hye KIM
Abstract: Provided are a compound having a chromane, isochromane, thiochromane, or tetrahydroquinoline moiety or pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical composition comprising the same and a use thereof, wherein the compound having a chromane, isochromane, thiochromane, or tetrahydroquinoline moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
Type:
Application
Filed:
November 12, 2020
Publication date:
January 5, 2023
Applicants:
YUHAN CORPORATION, GREEN CROSS CORPORATION
Abstract: The present invention relates to an improved method of purifying an immunoglobulin, and more particularly to a method of purifying an immunoglobulin which is capable of sufficiently removing impurities from an immunoglobulin-containing plasma protein sample through a simple process, comprising a single anion-exchange chromatography and a single cation-exchange chromatography.
Type:
Grant
Filed:
October 26, 2018
Date of Patent:
December 27, 2022
Assignee:
GREEN CROSS CORPORATION
Inventors:
Soo-kwang Kim, Kyung Hyun Boo, Kang Yun Seo, Sung Min Choi, Jeong Hye Yoon, Jin Hyun Park, Yeon Hui Kim
Abstract: Provided are a compound having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same and a use thereof, where the compound having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.
Type:
Application
Filed:
November 12, 2020
Publication date:
December 22, 2022
Applicants:
YUHAN CORPORATION, GREEN CROSS CORPORATION
Inventors:
Dong-Hoon KIM, Jae-Eun JOO, Eui-Chul LEE, Tae-Dong HAN, Seung-Yub SHIN, Sool-Ki KWON, Young-Gyu KONG, Sang-Ho MA, Ick-Hwan SON
Abstract: The present invention relates to a method for treating anemia using a long-acting EPO formulation, and more specifically, a method for treating patients with anemia by confirmation of safe, long-acting, and optimal effective dosage and usage in administering a fusion polypeptide which comprises an EPO and an immunoglobulin hybrid Fc to patients with anemia. The method of administering the fusion polypeptide employs an appropriate dosage and usage which not only shows an excellent long-acting property compared to the existing EPO products but also minimizes cardiovascular side effects that may occur due to a rapid increase in hemoglobin level, which is an effect of anemia treatment.
Type:
Grant
Filed:
January 8, 2016
Date of Patent:
December 13, 2022
Assignees:
GENEXINE, INC., GREEN CROSS CORPORATION
Inventors:
Sang-In Yang, Jung-Won Woo, Se Hwan Yang, Young Chul Sung, Doo Hong Park, Min Woo Kim
Abstract: The present invention relates to an anti-CD3 antibody and a pharmaceutical composition for cancer treatment comprising same. The antibody according to the present invention has high affinity and specificity for CD3 and thus can be effectively used in cancer prevention or treatment.
Type:
Grant
Filed:
October 22, 2018
Date of Patent:
November 15, 2022
Assignees:
GREEN CROSS CORPORATION, MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
Inventors:
Ki Su Kim, Jun Hong Jeong, Ae Rin Yoon, Eun Jung Song, Hye Ji Choi, Ok Jae Lim, Yun Jung Lee, Hyung Kwon Lim, Jong Wha Won
Abstract: Provided according to an embodiment of the present invention is an antibody that binds specifically to B-cell maturation antigen (BCMA) and comprises a heavy chain variable domain (VH domain) composed of a sequence having a homology of 80% or higher with any one of the amino acid sequences of SEQ ID NOS: 1 to 20, or a fragment thereof.
Type:
Grant
Filed:
September 21, 2018
Date of Patent:
September 20, 2022
Assignees:
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, GREEN CROSS CORPORATION, DANA-FARBER CANCER INSTITUTE, INC.
Inventors:
Hye-Ji Choi, Jae-Chan Park, Hyung-Kwon Lim
Abstract: A steric epitope of CEACAM1 is disclosed. An anti-CEACAM1 antibody or a fragment thereof, which specifically binds to CEACAM1 is disclosed. A steric epitope of CEACAM1 includes all amino acids in critical positions for specific binding to an anti-CEACAM1 antibody and maintains an appropriate three-dimensional structure, and thus can high affinity for an anti-CEACAM1 antibody. In addition, an antibody, or a fragment thereof, that specifically binds to a steric epitope can effectively suppress CEACAM1-CEACAM1 interaction and CEACAM1-CEACAM6 interaction.
Type:
Application
Filed:
November 7, 2019
Publication date:
September 15, 2022
Applicants:
GREEN CROSS CORPORATION, MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
Inventors:
Mi-Young OH, Jae-Chul LEE, Hye Young PARK, Hye In YUM, Dong-Sik KIM
Abstract: A fusion protein including a fragment of an anti-mesothelin antibody, an anti-CD3 antibody or an anti-EGFR antibody; a bispecific antibody that is specific to mesothelin and CD3; a trispecific antibody that is specific to mesothelin, CD3 and EGFR are provided. The fusion protein is effective in treating cancer. The bispecific or trispecific antibody can be prepared in a high yield and with high purity, and has excellent tumor killing and growth inhibitory effects, and thus can be effectively used in cancer treatment.
Type:
Application
Filed:
December 16, 2019
Publication date:
August 11, 2022
Applicants:
GREEN CROSS CORPORATION, MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
Inventors:
Yangmi LIM, Shinai LEE, Jonghwa WON, Yong-Yea PARK, Aerin YOON, Sua LEE, Okjae LIM, Sojung LIM, Munkyung KIM
Abstract: The present invention relates to an anti-MSLN antibody and a pharmaceutical composition for cancer treatment comprising same. The anti-MSLN antibody according to the present invention has high affinity and specificity for MSLN and thus can be effectively used in cancer prevention or treatment.
Type:
Grant
Filed:
October 22, 2018
Date of Patent:
August 2, 2022
Assignees:
GREEN CROSS CORPORATION, MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
Inventors:
Ki Su Kim, Jung Hong Jeong, Dong Sik Kim, Yang Mi Lim, Yong Yea Park, Hyung Kwon Lim, Jong Wha Won
Abstract: The present invention provides anti-CEACAM1 antibodies with improved binding abilities specific to CEACAM1, and a use thereof. Anti-CEACAM1 antibodies according to the present invention exhibit superior binding abilities specific to CEACAM1, and also activate the anti-cancer immune functions of cytotoxic T cells and natural killer cells, and thus, each one of them can be effectively used as an anti-cancer agent and a composition for treating cancer.
Type:
Grant
Filed:
March 23, 2018
Date of Patent:
May 17, 2022
Assignees:
MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, GREEN CROSS CORPORATION
Inventors:
So-Young Eun, Miyoung Oh, Hye-Young Park, Mijung Lee, Aerin Yoon, Hye In Yum, Hyemi Nam, Eunhee Lee, Jongwha Won
Abstract: A bispecific anti-GPNMB/anti-CD3 antibody specifically binds to CD3 (cluster of differentiation 3) and GPNMB (glycoprotein non-metastatic melanoma protein B) and uses thereof are disclosed. The bispecific antibody shows high affinity and specificity to CD3 and GPNMB and thus can induce death of cancer cells expressing GPNMB and inhibit proliferation thereof. Therefore, the bispecific antibody can be used as an effective therapeutic agent for cancers expressing GPNMB.
Type:
Application
Filed:
April 6, 2020
Publication date:
May 5, 2022
Applicant:
GREEN CROSS CORPORATION
Inventors:
Jae Chan PARK, Eun Jung SONG, So Jung LIM, Jae-Chul LEE, Hae Naem KWON, Su A LEE, Ok Jae LIM, Mun Kyung KIM, Hyun Jung CHO, Gil-Jung KIM, Jee Won LEE, Sung Keun KIM, Jong Wha WON, Shin A JANG
Abstract: A specific conformational epitope of a hepatitis B surface antigen and a hepatitis B neutralizing antibody binding thereto are disclosed. The epitope has a specific conformational structure. In addition, the conformational epitope does not contain the ‘a’ determinant that may generate an escape mutation upon administration of conventional vaccines or HBIg. Thus, an antibody capable of binding to the epitope is highly unlikely to allow the emergence of a vaccine escape mutation, which is caused by conventional vaccines, and as such, can retain a sustained effect. Therefore, such an antibody or a vaccine composition can find effective applications in the prevention and treatment of HBV, having great economic value.
Abstract: The present disclosure relates to a pharmaceutical highly efficient anti-TFPI antibody composition including an anti-TFPI antibody for treating hemophilia, in which the content of HCP in a drug substance is less than 10.0 ng/mg, and the content of LPA in the drug substance or the drug product is less than 1.0 ng/mg. According to the present disclosure, a highly efficient anti-TFPI antibody composition having very low contents of HCP and LPA may be provided by providing a separation/purification process capable of minimizing anti-TFPI antibody polymer generation, and may be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease.
Type:
Application
Filed:
September 6, 2019
Publication date:
January 27, 2022
Applicant:
GREEN CROSS CORPORATION
Inventors:
Min Jung KIM, Geun Hye YEO, Haeng Eun SONG, Ji Yoon PARK, Yuna KIM
Abstract: The present invention provides a pharmaceutical composition for inhibiting the metastasis of cancer, comprising, as an active ingredient, an antibody that specifically binds to an epidermal growth factor receptor, and a method for inhibiting the metastasis of cancer using the composition. The composition or the method is effective in inhibiting the invasion of various gastric cancer cell lines induced by EGFR ligands. Therefore, the pharmaceutical composition can be usefully used for inhibiting the metastasis of cancer.
Type:
Grant
Filed:
April 27, 2016
Date of Patent:
December 14, 2021
Assignees:
GREEN CROSS CORPORATION, MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH